within Pharmacolibrary.Drugs.C_CardiovascularSystem.C04A_PeripheralVasodilators.C04AX01_Cyclandelate;
model Cyclandelate 
   extends Pharmacolibrary.Drugs.ATC.C.C04AX01;

  annotation(Documentation(
    info ="<html><body><p>Cyclandelate is a vasodilator that was used in the treatment of peripheral vascular diseases, such as intermittent claudication and cerebrovascular insufficiency. It acts by relaxing vascular smooth muscle but is no longer widely approved or used due to limited evidence of clinical benefit and the availability of more effective therapies.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic model parameters for an average healthy adult after oral administration. No recent or high-quality published PK studies available.</p><h4>References</h4><ol><li><p>Kaniwa, N, et al., &amp; Imazato, Y (1991). Effect of food on the bioavailability of cyclandelate from commercial capsules. <i>Clinical pharmacology and therapeutics</i> 49(6) 641–647. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1991.81&quot;>10.1038/clpt.1991.81</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2060253/&quot;>https://pubmed.ncbi.nlm.nih.gov/2060253</a></p></li><li><p>Dimpfel, W, et al., &amp; Coors, C (1994). [Evidence of a pharmacokinetic-pharmacodynamic relationship between pharmaco-EEG in healthy subjects after administration of cyclandelate]. <i>Arzneimittel-Forschung</i> 44(9) 999–1004. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7986255/&quot;>https://pubmed.ncbi.nlm.nih.gov/7986255</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Cyclandelate;
